
Inhibition of mPGES-1 is a well-developed area of preclinical research with studies showing that its genetic deletion protects against inflammation, pain and cancer (Friesen, R.W. and Mancini, J. A., *J Med Chem.*, **51**, 4059-4067 (2008); Howe, L. R. *et al.*, *Prostaglandins Other Lipid Mediat.*, **106**, 99-105 (2013); Korotkova, M. and Jakobsson P. J., *Basic Clin Pharmacol Toxicol*., **114**, 64-69 (2014)). However, the lack of a complete understanding surrounding cardiovascular toxicity and other negative effects has meant that research and translation of mPGES-1 as a therapeutic target to replace COX-2 in the treatment of a wide range of diseases and disorders has been restricted.

WO 2012/022793 A1 describes the use of various mPGES-1 inhibitors in the treatment of a range of inflammatory disorders. WO 2017/144909 A1 describes the use of various mPGES-1 inhibitors in the treatment of diseases and disorders characterised by vasoconstriction. These disclosures do not teach or suggest the treatment or prophylaxis of endometriosis.

Summary

In an aspect, there is provided the use of a compound of formula I



(I)

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treatment or prophylaxis of endometriosis.

In another aspect, there is provided the use of a pharmaceutical formulation comprising a compound of formula I as defined above, or a pharmaceutically acceptable salt thereof, and optionally one or more pharmaceutically acceptable excipients, in the manufacture of a medicament for treatment or prophylaxis of endometriosis.

In another aspect, there is provided a combination product comprising:

(I) a compound of formula I as defined above, or a pharmaceutically acceptable salt thereof; and

(II) one or more other therapeutic agent useful in the treatment or prophylaxis of endometriosis,

wherein each of components (I) and (II) is formulated in admixture, optionally with one or more a pharmaceutically-acceptable excipient.

In another aspect, there is provided a kit-of-parts comprising:

(a) a pharmaceutical formulation as defined above; and


(b) a pharmaceutical formulation comprising one or more other therapeutic agent useful in the treatment or prophylaxis of endometriosis, optionally in admixture with one or more pharmaceutically-acceptable excipients,

wherein components (a) and (b) are each provided in a form that is suitable for administration in conjunction with the other.

Description of the Invention

We have now surprisingly found that a particular compound as described herein is an effective agent for the treatment or prophylaxis of endometriosis.

In a first aspect of the invention, there is provided a compound of formula I




(I)

or a pharmaceutically acceptable salt thereof, for use in the treatment or prophylaxis of endometriosis.

In an alternative first aspect of the invention, there is provided a method for the treatment or prophylaxis of endometriosis, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula I as defined herein, or a pharmaceutically acceptable salt thereof

Claims

1. Use of a compound of formula I



(I)

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treatment or prophylaxis of endometriosis.

2. Use of a pharmaceutical formulation comprising a compound of formula I as defined in Claim 1, or a pharmaceutically acceptable salt thereof, and optionally one or more pharmaceutically acceptable excipients, in the manufacture of a medicament for treatment or prophylaxis of endometriosis.

3. A combination product comprising:

(I) a compound of formula I as defined in Claim 1, or a pharmaceutically acceptable salt thereof; and

(II) one or more other therapeutic agent useful in the treatment or prophylaxis of endometriosis,

wherein each of components (I) and (II) is formulated in admixture, optionally with one or more a pharmaceutically-acceptable excipient.

4. A kit-of-parts comprising:

(a) a pharmaceutical formulation as defined in Claim 2; and

(b) a pharmaceutical formulation comprising one or more other therapeutic agent useful in the treatment or prophylaxis of endometriosis, optionally in admixture with one or more pharmaceutically-acceptable excipients,

wherein components (a) and (b) are each provided in a form that is suitable for administration in conjunction with the other.